Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001224839 | SCV001397062 | pathogenic | not provided | 2023-10-30 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 421 of the SLC12A3 protein (p.Cys421Arg). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features consistent with Gitelman syndrome and/or Gitelman syndrome (PMID: 8528245; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8585). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC12A3 protein function with a positive predictive value of 95%. This variant disrupts the p.Cys421 amino acid residue in SLC12A3. Other variant(s) that disrupt this residue have been observed in individuals with SLC12A3-related conditions (PMID: 17699451, 21415153, 27454426, 27582097, 30596175), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000009116 | SCV000029333 | pathogenic | Familial hypokalemia-hypomagnesemia | 1996-01-01 | no assertion criteria provided | literature only | |
Natera, |
RCV000009116 | SCV002089348 | pathogenic | Familial hypokalemia-hypomagnesemia | 2020-03-15 | no assertion criteria provided | clinical testing |